Thermo Fisher Scientific Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Performance::

Revenue: $12.21 billion (up 7% YoY)

Adjusted Operating Income: $2.88 billion (up 6% YoY)

Adjusted Operating Margin: 23.6%

Adjusted EPS: $6.57 (up 8% YoY)

Full Year 2025 Performance::

Revenue: $44.56 billion (up 4% YoY)

Adjusted Operating Income: $10.11 billion (up 4% YoY)

Adjusted Operating Margin: 22.7%

Adjusted EPS: $22.87 (up 5% YoY)

2Strategic Updates and Business Highlights

Market Performance::

Pharma and biotech segments showed high single-digit growth in Q4, driven by bioproduction and clinical research.

Academic and government markets faced low single-digit declines due to macroeconomic conditions.

Industrial and applied markets grew slightly for the year, while diagnostics and healthcare remained flat.

Growth Strategy::

Focused on high-impact innovation, trusted partnerships, and a strong commercial engine.

Key product launches included advancements in mass spectrometry and bioproduction technologies.

Strategic partnerships with organizations like OpenAI and Chan Zuckerberg for enhanced capabilities.

Capital Deployment::

Approximately $16.5 billion deployed in 2025, including $13 billion on M&A and $3.6 billion returned to shareholders.

Notable acquisitions included the filtration business from Solventa and a sterile fill-finish site from Sanofi.

3Forward Guidance and Outlook

2026 Guidance::

Revenue expected between $46.3 billion and $47.2 billion, representing 4% to 6% growth.

Adjusted EPS guidance of $24.22 to $24.80, indicating 6% to 8% growth.

Assumes 3% to 4% organic growth and includes a $300 million revenue tailwind from foreign exchange.

4Bad News, Challenges, or Points of Concern

Market Pressures::

Academic and government segments remain cautious, with potential delays in spending until a finalized NIH budget is passed.

The company faces ongoing headwinds from tariffs and foreign exchange volatility, impacting margins.

Declines in the academic market and pressures in China were noted as challenges.

Operational Risks::

The guidance does not account for potential future changes in tariffs or their impact on foreign exchange rates.

The integration of recent acquisitions may present challenges in achieving projected synergies.

5Notable Q&A Insights

Market Conditions::

Management expressed cautious optimism regarding biopharma spending, noting a lag between funding flows and actual spending.

The sentiment among pharma customers appears positive, with expectations for increased activity in 2026.

Analytical Instruments Performance::

The segment faced a tough comparison but managed to maintain flat growth, supported by strong performance in pharma and biotech.

Customer Engagement::

Management highlighted the importance of being a trusted partner, with positive feedback from customers indicating a willingness to collaborate on specific projects. Overall, Thermo Fisher Scientific closed 2025 with strong financial performance and a positive outlook for 2026, despite facing challenges in certain market segments and external economic pressures.